Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech ( (EVAX) ) has provided an update.
Evaxion Biotech A/S has announced its Articles of Association, focusing on the issuance of warrants and potential capital increases. The board is authorized to issue warrants and increase share capital up to a nominal value of DKK 9,461,540, aligning with their strategic goals to enhance shareholder value and operational flexibility.
More about Evaxion Biotech
Evaxion Biotech A/S is a biotechnology company that specializes in creating advanced software to develop novel immune therapies and vaccines. It operates under the secondary name NovVac A/S.
YTD Price Performance: 2.81%
Average Trading Volume: 342,920
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.14M
See more data about EVAX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts